XTAL Tech Surges Over 6% to Hit 3-Month High, Up Over 50% YTD as Portfolio Company’s RTX-117 Receives IND Approvals in US and China

Gelonghui January 14 | XtalPi Holdings Limited (2228.HK), an innovative platform enterprise that empowers new drug and new material R&D with AI + robotics, once rose 6.17% to HKD 14.28 in the morning trading session today, hitting a more than three-month high since October 10, 2025. Since the beginning of 2026, the stock price has surged 50.95% over nine trading days, significantly outperforming the broader market (during the same period, the Hang Seng Index rose over 5%).

XtalPi announced earlier this morning that RTX-117, an innovative drug pipeline from its incubated company ReviR Therapeutics, has successfully achieved the significant milestone of "dual filing and dual approval" (IND approval) in both China and the U.S. Combined with the successful progress of several collaborations, XtalPi will receive milestone payments totaling tens of millions of Hong Kong dollars from ReviR. ReviR will continue to advance the subsequent clinical development of RTX-117, while XtalPi is entitled to participate in the sales revenue sharing and subsequent licensing revenue sharing of this pipeline.

It is reported that RTX-117 is the first milestone achievement in a series of R&D pipelines from the deep collaboration between XtalPi and ReviR. Both the preclinical data and the speed of clinical approval have exceeded the expectations of both parties. In addition, RTX-117 not only applies to the current CMT patient population but also has significant potential for indication expansion, with a potential target population estimated to exceed 50 million, nearly 20 times the current number of CMT patients. (Gelonghui)